Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth
Bulletin of Mathematical Biology · 2024
DOI: 10.1007/s11538-024-01272-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Mathematical Biology, 2024. Verfasst von Mason S Lacy und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Queensland University of Technology.
Abstract (Originalsprache)
Resistance of cancers to treatments, such as chemotherapy, largely arise due to cell mutations. These mutations allow cells to resist apoptosis and inevitably lead to recurrence and often progression to more aggressive cancer forms. Sustained-low dose therapies are being considered as an alternative over maximum tolerated dose treatments, whereby a smaller drug dosage is given over a longer period of time. However, understanding the impact that the presence of treatment-resistant clones may have on these new treatment modalities is crucial to validating them as a therapeutic avenue. In this study, a Moran process is used to capture stochastic mutations arising in cancer cells, inferring treatment resistance. The model is used to predict the probability of cancer recurrence given varying treatment modalities. The simulations predict that sustained-low dose therapies would be virtually ineffective for a cancer with a non-negligible probability of developing a sub-clone with resistance tendencies. Furthermore, calibrating the model to in vivo measurements for breast cancer treatment with Herceptin, the model suggests that standard treatment regimens are ineffective in this mouse model. Using a simple Moran model, it is possible to explore the likelihood of treatment success given a non-negligible probability of treatment resistant mutations and suggest more robust therapeutic schedules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
- School of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. adrianne.jenner@qut.edu.au.
ORCID-Profile: Adrianne L Jenner
Förderung
- Queensland University of Technology
Zitieren
APA
Lacy, M. S., & Jenner, A. L. (2024). Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth. Bulletin of Mathematical Biology. https://doi.org/10.1007/s11538-024-01272-6
Vancouver
Lacy MS, Jenner AL. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth. Bulletin of Mathematical Biology. 2024. doi:10.1007/s11538-024-01272-6
BibTeX
@article{Lacy2024,
author = {Lacy, Mason S and Jenner, Adrianne L},
title = {Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth},
journal = {Bulletin of Mathematical Biology},
year = {2024},
doi = {10.1007/s11538-024-01272-6}
}
EUVIMED